Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neramexane extension in nystagmus
NCT00799942Phase 2Terminated
- Sponsor
- Merz
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neramexane in congenital nystagmus and Acquired nystagmus, sponsored by Merz. Primary endpoints: Long-term safety and Visual acuity. Started May 2009; status: terminated.
02
Drugs
neramexane
03
Conditions
congenital nystagmusAcquired nystagmus
Beyond the preview
Go deeper on NCT00799942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00799942.